These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26179851)

  • 1. [Changing the paradigm: valsartan-inhibitor of neprilysin, a new dual-acting drug for arterial hypertension and heart failure].
    Galve E; Casas-Masnou G; García-Dorado D
    Hipertens Riesgo Vasc; 2015; 32(1):1-5. PubMed ID: 26179851
    [No Abstract]   [Full Text] [Related]  

  • 2. Valsartan in chronic heart failure.
    Haddy FJ
    N Engl J Med; 2002 Apr; 346(15):1173-4. PubMed ID: 11948282
    [No Abstract]   [Full Text] [Related]  

  • 3. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
    Cohn JN
    Am J Cardiol; 2002 Nov; 90(9):992-3. PubMed ID: 12398968
    [No Abstract]   [Full Text] [Related]  

  • 4. Dual-acting angiotensin receptor-neprilysin inhibition.
    Segura J; Ruilope LM
    Curr Hypertens Rep; 2011 Feb; 13(1):74-8. PubMed ID: 21046489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    McMurray JJ
    Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):128-9. PubMed ID: 16265452
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Hollenberg NK
    Curr Hypertens Rep; 2002 Dec; 4(6):411; discussion 412. PubMed ID: 12462208
    [No Abstract]   [Full Text] [Related]  

  • 7. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
    Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
    Krum H; Carson P; Farsang C; Maggioni AP; Glazer RD; Aknay N; Chiang YT; Cohn JN
    Eur J Heart Fail; 2004 Dec; 6(7):937-45. PubMed ID: 15556056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VALUE: to the heart of the matter.
    Staessen JA; Birkenhäger WH
    J Hypertens; 2004 Aug; 22(8):1431-4. PubMed ID: 15257159
    [No Abstract]   [Full Text] [Related]  

  • 11. [Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
    MMW Fortschr Med; 2006 Feb; 148(5):48-9. PubMed ID: 16518941
    [No Abstract]   [Full Text] [Related]  

  • 12. [Angiotensin I receptor blockers for heart failure].
    Fruhwald FM; Kickenweiz E; Zweiker R; Klein W
    Wien Med Wochenschr; 2001; 151(7-8):157-9. PubMed ID: 11450163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VALIANT trial results support use of valsartan in acute myocardial infarction.
    Cardiovasc J S Afr; 2004; 15(1):45, 47. PubMed ID: 15095754
    [No Abstract]   [Full Text] [Related]  

  • 14. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valsartan in chronic heart failure.
    Campbell DJ
    N Engl J Med; 2002 Apr; 346(15):1173-4. PubMed ID: 11951863
    [No Abstract]   [Full Text] [Related]  

  • 17. Valsartan in chronic heart failure.
    Forfar JC; Munir S
    N Engl J Med; 2002 Apr; 346(15):1173-4. PubMed ID: 11951862
    [No Abstract]   [Full Text] [Related]  

  • 18. AT1-receptor blockers.
    Petkun W
    Eur Heart J; 2000 Feb; 21(4):335-7. PubMed ID: 10653684
    [No Abstract]   [Full Text] [Related]  

  • 19. Valsartan: new preparation. Just a second-line antihypertensive drug.
    Prescrire Int; 1998 Oct; 7(37):144-5. PubMed ID: 10915419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of recent clinical trials for heart failure performance measures.
    Executive Council Of The Heart Failure Society Of America
    J Card Fail; 2004 Feb; 10(1):4-5. PubMed ID: 14966767
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.